A compound or pharmaceutically acceptable salt thereof for use in a method of treating a condition in a mammal, wherein the condition is selected from dry eye, blepharitis, meibomian gland disease, allergic conjunctivitis, pterygium, ocular symptoms of graft versus host disease, ocular allergy, atopic keratoconjunctivitis, vernal keratoconjunctivitis, uveitis, anterior uveitis, Behcet's disease, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, chronic ocular surface inflammation caused by viral infection, herpes simplex keratitis, ocular rosacea, pinguecula, to prevent corneal transplant rejection, and to restore corneal sensitivity that has been impaired due to surgery on the cornea or other surface of the eye; and wherein said compound is of formula: wherein: A represents -CH=CHR, -CH=CH-CH=CHR, or -CH 2 CH 2 R, wherein R represents - CH 3; -CH 2 SH; -CH 2 S-C n, wherein n=1-6; -CH 2 -carboxyl; carboxyl; wherein R=C 1 -C 6 alkyl; or wherein R=C 1 -C 6 alkyl; B represents -CH 2 CH 3, 1-hydroxyethyl, isopropyl or n-propyl; C represents isobutyl, 2-hydroxyisobutyl or 1-methylpropyl; D represents -CH 3 or -CH 2 OH; R 1 and R 2, which are identical or different, independently represent C 1 -C 6 alkyl or mono, di, or trifluorinated alkyl; R 1 and R 2, together with the nitrogen atom to which they are attached, may form a saturated or partially unsaturated 3-7 member heterocycloalkyl containing one other heteroatom selected from oxygen, S n, wherein n=0,1,2; and nitrogen which is optionally substituted with C 1 -C 6 alkyl or fluoroalkyl. wherein the condition is selected from dry eye, blepharitis, meibomian gland disease, allergic conjunctivitis, pterygium, ocular symptoms of graft versus host disease, ocular allergy, atopic keratoconjunctivitis, vernal keratoconjunctivitis, uveitis, anterior uveitis, Behcet's disease, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, chronic ocular surface inflammation caused by viral infection, herpes simplex keratitis, ocular rosacea, pinguecula, to prevent corneal transplant rejection, and to restore corneal sensitivity that has been impaired due to surgery on the cornea or other surface of the eye; and wherein said compound is of formula: wherein: A represents -CH=CHR, -CH=CH-CH=CHR, or -CH 2 CH 2 R, wherein R represents - CH 3; -CH 2 SH; -CH 2 S-C n, wherein n=1-6; -CH 2 -carboxyl; carboxyl; wherein R=C 1 -C 6 alkyl; or wherein R=C 1 -C 6 alkyl; B represents -CH 2 CH 3, 1-hydroxyethyl, isopropyl or n-propyl; C represents isobutyl, 2-hydroxyisobutyl or 1-methylpropyl; D represents -CH 3 or -CH 2 OH; R 1 and R 2, which are identical or different, independently represent C 1 -C 6 alkyl or mono, di, or trifluorinated alkyl; R 1 and R 2, together with the nitrogen atom to which they are attached, may form a saturated or partially unsaturated 3-7 member heterocycloalkyl containing one other heteroatom selected from oxygen, S n, wherein n=0,1,2; and nitrogen which is optionally substituted with C 1 -C 6 alkyl or fluoroalkyl. A represents -CH=CHR, -CH=CH-CH=CHR, or -CH 2 CH 2 R, wherein R represents - CH 3; -CH 2 SH; -CH 2 S-C n, wherein n=1-6; -CH 2 -carboxyl; carboxyl; wherein R=C 1 -C 6 alkyl; or wherein R=C 1 -C 6 alkyl; B represents -CH 2 CH 3, 1-hydroxyethyl, isopropyl or n-propyl; C represents isobutyl, 2-hydroxyisobutyl or 1-methylpropyl; D represents -CH 3 or -CH 2 OH; R 1 and R 2, which are identical or different, independently represent C 1 -C 6 alkyl or mono, di, or trifluorinated alkyl; R 1 and R 2, together with the nitrogen atom to which they are attached, may form a saturated or partially unsaturated 3-7 member heterocycloalkyl containing one other heteroatom selected from oxygen, S n, wherein n=0,1,2; and nitrogen which is optionally substituted with C 1 -C 6 alkyl or fluoroalkyl.